Pharmaceutical sales for age-related macular degeneration (AMD) marketplaces were projected to be $4.9 billion in 2016, and it’s expected to reach a price of $11.5 billion in 2026, with a Compound Annual Growth Rate (CAGR) rise of 8.9%, stated by a leading data and analytics company.

According to a company report states that this growth will be driven by new therapies entering the market and a global aging society, which will lead to increasing numbers of elderly people developing AMD.

Some of the predictions made by a leading data and analytics company that the launches of three drugs for the treatment of geographic atrophy (GA), the late stage of dry age-related macular degeneration (dAMD), and three late-stage pipeline drugs for wet AMD (wAMD). In particular, the launch of drugs into the AMD market to treat dAMD will be a large driver of growth, as there are currently no prescription medications available for these patients.

Healthcare expert comments as: “We expect that with the launch of brolucizumab in the wAMD market, Novartis will offset the losses to Eylea and regain dominance in the AMD market. Once more efficacy and safety data collects and physicians become more accustomed to the use of brolucizumab, its advantage of less frequent dosing will allow it to claim an increasing share and become a first-line therapy if reimbursed.”

Key opinion leaders interviewed by GlobalData emphasized that pricing will also play a key role in the uptake of brolucizumab. Novartis’ brolucizumab is estimated to reach an epic status by 2021, and will be the highest selling drug by 2026 among all drugs launching to the AMD market, with $4.1bn in global sales.

New drugs entering the dAMD market will include two anti-complement agents: Apellis’ APL-2 and Ophthotech’s Zimura, and one neuroprotective agent, Allergan’s Brimo DDS, which together will drive an increase of the treated AMD cases, expanding the AMD market.

Further the expert added “Due to the failure of each clinical test of Phase III trials of lampalizumab for the treatment of GA, Apellis’ APL-2 emerged because the most promising GA drug once it’s positive Phase IIa results were declared. Provided that the planned Phase III trial of APL-2 for GA will confirm these results, we forecast that Apellis’ drug will reach blockbuster status within a few years of its launch, by 2025.”

Table of Contents

Table of Contents

1 Table of Contents

1.1 List of Tables

1.2 List of Figures

2 Age-Related Macular Degeneration: Executive Summary

2.1 Significant Growth Expected in the AMD Market from 2016 to 2026

2.2 R&D and Corporate Strategies Within the AMD Market

2.3 Current Therapies for AMD Leave Abundant Unmet Needs

2.4 Opportunities Will Remain for New Entrants

2.5 Late-Stage Pipeline Drugs Entering the AMD Market Will Be a Key Driver of Growth

2.6 What Do Physicians Think?

3 Introduction

3.1 Catalyst

3.2 Related Reports

3.3 Upcoming Related Reports

4 Disease Overview

4.1 Etiology and Pathophysiology

4.1.1 Overview

4.1.2 dAMD

4.1.3 wAMD

4.1.4 Genetic Targets of Interest

4.2 Classification

4.3 Symptoms

4.4 Prognosis

5 Epidemiology

5.1 Disease Background

5.2 Risk Factors and Comorbidities

5.3 Global and Historical Trends

5.4 Forecast Methodology

5.4.1 Sources Used

5.4.2 Forecast Assumptions and Methods

5.4.3 Total Prevalent Cases of AMD, Early AMD, Late AMD, Late Dry AMD, Late Wet AMD, and Large Drusen

5.4.4 Diagnosed Incident Cases of AMD, Early AMD, Late AMD, Late Dry AMD, Late Wet AMD, and Large Drusen

5.5 Epidemiological Forecast for AMD (2016–2026)

5.5.1 Total Prevalent Cases of AMD

5.5.2 Age-Specific Total Prevalent Cases of AMD

5.5.3 Sex-Specific Total Prevalent Cases of AMD

5.5.4 Total Prevalent Cases of Early AMD

5.5.5 Total Prevalent Cases of Late AMD

5.5.6 Total Prevalent Cases of Late Dry AMD

5.5.7 Total Prevalent Cases of Late Wet AMD

5.5.8 Total Prevalent Cases of Large Drusen

5.5.9 Diagnosed Incident Cases of AMD

5.5.10 Age-Specific Diagnosed Incident Cases of AMD

5.5.11 Sex-Specific Diagnosed Incident Cases of AMD

5.5.12 Diagnosed Incident Cases of Early AMD

5.5.13 Diagnosed Incident Cases of Late AMD

5.5.14 Diagnosed Incident Cases of Late Dry AMD

5.5.15 Diagnosed Incident Cases of Late Wet AMD

5.5.16 Diagnosed Incident Cases of Large Drusen

5.6 Discussion

5.6.1 Epidemiological Forecast Insight

5.6.2 Limitations of the Analysis

5.6.3 Strengths of the Analysis

6 Disease Management

6.1 Diagnosis Overview

6.2 Treatment Overview

6.2.1 Treatment Guidelines and Leading Prescribed Drugs

6.2.2 Clinical Practice

6.2.3 dAMD

6.2.4 wAMD

7 Competitive Assessment

7.1 Overview

7.2 Lucentis (Ranibizumab)

7.2.1 Overview

7.2.2 Efficacy

7.2.3 Safety

7.2.4 Forecast

7.3 Avastin (Bevacizumab)

7.3.1 Overview

7.3.2 Efficacy

7.3.3 Safety

7.3.4 SWOT Analysis

7.3.5 Forecast

7.4 Eylea (Aflibercept)

7.4.1 Overview

7.4.2 Efficacy

7.4.3 Safety

7.4.4 SWOT Analysis

7.4.5 Forecast

7.5 Macugen (Pegaptanib Sodium)

7.5.1 Overview

7.5.2 Efficacy

7.5.3 Safety

7.6 Visudyne (Verteporfin)

7.6.1 Overview

7.6.2 Efficacy

7.6.3 Safety

7.6.4 SWOT Analysis

7.6.5 Forecast

8 Unmet Needs and Opportunity Assessment

8.1 Overview

8.2 Treatment for Dry AMD

8.2.1 Unmet Need

8.2.2 Gap Analysis

8.2.3 Opportunity

8.3 Longer Acting Therapy

8.3.1 Unmet Need

8.3.2 Gap Analysis

8.3.3 Opportunity

8.4 Increased Anti-VEGF Efficacy

8.4.1 Unmet Need

8.4.2 Gap Analysis

8.4.3 Opportunity

8.5 Less Invasive Formulations

8.5.1 Unmet Need

8.5.2 Gap Analysis

8.5.3 Opportunity

8.6 Early Diagnosis and Disease Management

8.6.1 Unmet Need

8.6.2 Gap Analysis

8.6.3 Opportunity

9 Pipeline Assessment

9.1 Overview

9.2 Clinical Trial Mapping

9.2.1 Clinical Trials by Patient Population

9.3 Promising Drugs in Clinical Development

9.3.1 Brolucizumab

9.3.2 Abicipar pegol

9.3.3 OPT-302

9.3.4 APL-2

9.3.5 Zimura

9.3.6 Brimo DDS

9.4 Promising Drugs in Early-Stage Development

9.4.1 Complement Inhibitors

9.4.2 Anti-Angiogenic Agent

9.4.3 Anti-angiogenic (Topical)

9.4.4 Anti-angiogenic (Oral)

9.4.5 Anti-Fibrotic Agent

9.4.6 Stem Cell Therapy

9.5 Other Drugs in Development

9.6 Biosimilars

10 Current and Future Players

10.1 Overview

10.2 Trends in Corporate Strategy

10.3 Roche/Genentech

10.3.1 Overview

10.3.2 Portfolio Assessment

10.4 Novartis/Alcon

10.4.1 Overview

10.4.2 Portfolio Assessment

10.5 Regeneron

10.5.1 Overview

10.5.2 Portfolio Assessment

10.6 Bayer

10.6.1 Overview

10.6.2 Portfolio Assessment

10.7 Valeant

10.7.1 Overview

10.7.2 Portfolio Assessment

10.8 Allergan

10.8.1 Overview

10.8.2 Portfolio Assessment

10.9 Ohr Pharmaceutical

10.9.1 Overview

10.9.2 Portfolio Assessment

10.10 Apellis

10.10.1 Overview

10.10.2 Portfolio Assessment

10.11 Ophthotech

10.11.1 Overview

10.11.2 Portfolio Assessment

10.12 Opthea

10.12.1 Overview

10.12.2 Portfolio Assessment

11 Market Outlook

11.1 Global Markets

11.1.1 Forecast

11.1.2 Drivers and Barriers – Global Issues

11.2 US

11.2.1 Forecast

11.2.2 Key Events

11.2.3 Drivers and Barriers

11.3 5EU

11.3.1 Forecast

11.3.2 Key Events

11.3.3 Drivers and Barriers

11.4 Japan

11.4.1 Forecast

11.4.2 Key Events

11.4.3 Drivers and Barriers

12 Appendix

12.1 Bibliography

12.2 Abbreviations

12.3 Methodology

12.3.1 Forecasting Methodology

12.3.2 Diagnosed Patients

12.3.3 Percent Drug-Treated Patients

12.3.4 Drugs Included in Each Therapeutic Class

12.3.5 General Pricing Assumptions

12.3.6 Individual Drug Assumptions

12.3.7 Generic Erosion

12.3.8 Pricing of Pipeline Agents

12.4 Primary Research – KOLs Interviewed for This Report

12.5 Primary Research – Prescriber Survey

12.6 About the Authors

12.6.1 Analyst

12.6.2 Therapy Area Director

12.6.3 Epidemiologist

12.6.4 Managing Epidemiologist

12.6.5 Global Director of Therapy Analysis and Epidemiology

12.6.6 Global Head and EVP of Healthcare Operations and Strategy

12.7 About GlobalData

12.8 Contact Us

12.9 Disclaimer

Key benefits of buying this profile include:

  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
  • Develop business strategies by understanding the trends shaping and driving the global AMD therapeutics market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global AMD therapeutics market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

About GlobalData 

GlobalData is a leading provider of global business intelligence including market, competitor, and product and customer information. It provides in-depth research, analysis, data and forecasts through a range of interactive online databases, reports and management briefings. GlobalData has a large team of experienced research and analysis, consulting, and marketing experts. It has a global presence, including key offices in the US, Europe, and Asia. The group has over 50 years of experience of delivering market intelligence data and analysis and a highly experienced senior management team.

About is a syndicated report platform with a wide variety of industry reports from reputed industry publishers. is promoted by DART Consulting. lists the variety of reports at the best price with seasonal discounts and promotion codes.

This report is available at

Contact us:

Direct: + 91-80- 4224 7136, 953-807- 6063


Share :